Company Profile

AstraZeneca Pharma is planning to launch Acalabrutinib 100mg capsules (Calquence) in India on October 21, 2020. Acalabrutinib100mg capsules Calquence is indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It is also indicated for treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

Astrazeneca Pharma India is currently trading at Rs. 4297.00, up by 30.35 points or 0.71% from its previous closing of Rs. 4266.65 on the BSE.

The scrip opened at Rs. 4279.00 and has touched a high and low of Rs. 4321.05 and Rs. 4271.40 respectively. So far 578 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 4970.00 on 08-Sep-2020 and a 52 week low of Rs. 1888.00 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 4339.85 and Rs. 4209.60 respectively. The current market cap of the company is Rs. 10730.00 crore.

The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 4.58% and 20.42% respectively.

AstraZeneca Pharma is planning to launch Acalabrutinib 100mg capsules (Calquence) in India on October 21, 2020. Acalabrutinib100mg capsules Calquence is indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It is also indicated for treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

With reference to letter dated August 10, 2020, wherein the Company had informed that the Interim Dividend declared by the Board of Directors at their meeting held on August 10, 2020 shall be paid on or before September 8, 2020, Astrazeneca Pharma India has confirmed that the Company has completed dispatch of interim dividends through electronic mode to all those shareholders whose bank accounts were registered with the Company/ Depositories. However, with regard to those shareholders whose bank account details are not registered the physical instruments for the dividends are being dispatched to their registered address. In view of the current COVID-19 pandemic situation, the physical dispatches is taking a slightly longer time than usual. The Company is making best efforts to ensure that the physical instruments/ DDs are dispatched within best possible timelines.

The above information is a part of company’s filings submitted to BSE.

Astrazeneca Pharma India has informed that a meeting of the Board of Directors of the company will be held on Monday, August 10, 2020 to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2020 and consider declaration of an Interim Dividend to the equity shareholders of the Company for the financial year 2020-21. The company has informed that the ‘Trading Window’ remains closed for all Designated Persons, from June 16, 2020 to August 12, 2020 in terms of the company Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.

The above information is a part of company’s filings submitted to BSE.

Astrazeneca Pharma India has informed that pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Company enclosed the notice of the 41st Annual General Meeting (AGM) of the Company scheduled to be held on Monday, August 10, 2020 at 3.00 pm (IST) through Video Conferencing (VC)/ Other Audio Visual Means (OAVM). The Notice is being sent to the members of the Company through electronic mode. The said Notice and the Annual Report for the financial year ended March 31, 2020 is also available on the website of the Company at www.astrazeneca.com/india.

The above information is a part of company’s filings submitted to BSE.